Goldman Sachs initiates Hensoldt at Neutral with €85 target, cites valuation

Goldman Sachs initiated coverage of Hensoldt with a Neutral rating and an €85 price target, implying about 2.9% upside from the €82.58 reference price. The bank cited a record €10.36 billion backlog at end-H1 2026, up 17% from year-end 2025, and forecasts 2026 revenue of €2.8 billion and adjusted EBITDA of €530 million. Goldman expects revenue to reach €5.8 billion by 2030, but says the shares already reflect much of the growth outlook and its estimate is about 4% below Hensoldt’s €6 billion ambition.

Analysis

Hensoldt’s key risk is not demand visibility but converting a policy-led backlog into shipped systems, margins and cash. A high book-to-bill can support estimates, yet it also raises execution exposure: component bottlenecks, customer acceptance delays or working-capital absorption could defer cash realization even while reported orders remain strong. Germany’s revenue concentration amplifies both sides—procurement acceleration benefits Hensoldt, but budget slippage or program reprioritization would have an outsized effect. Competitors with overlapping air-defense and sensor offerings, including Rheinmetall and Thales, may capture orders if delivery capacity becomes the constraint; this is a potential substitution effect, not evidence of current share loss.

Near term, a neutral initiation and limited target-implied upside offer little fresh catalyst. Over 1–3 months, watch contract awards, delivery cadence and cash conversion rather than headline backlog. Over 6–18 months, sustained margin expansion and backlog conversion could justify premium earnings multiples; persistent delays or weaker cash generation would challenge them. The contrarian point: order visibility is not equivalent to earnings quality, and the market may be capitalizing procurement expectations before execution is demonstrated. Conversely, a premium valuation alone is not a short thesis while estimates and delivery remain intact.

Key Decisions for Investors

• Do not chase HAG on this initiation: the cited target leaves little near-term valuation cushion, while the note itself adds no company-specific catalyst. Reassess after results or contract updates provide evidence of conversion.
• Keep HAG on a conditional pullback-buy list only if order delivery, margins and operating cash conversion track management guidance; avoid adding solely on backlog growth.
• For a relative-value expression, consider underweighting HAG versus a diversified European defense basket only after confirming a meaningful valuation premium and stronger delivery/FCF performance among peers. The article does not provide peer multiples, so this is a watch item, not a current pair recommendation.
• Thesis falsifiers: repeated shipment or program delays, weakening book-to-bill, margin guidance cuts, or cash conversion deteriorating despite revenue growth would support reducing exposure. Faster backlog conversion with improving cash generation would invalidate the cautious stance.